Serum Unsaturated Free Fatty Acids: A Potential Biomarker Panel for Early-Stage Detection of Colorectal Cancer

Background: To screen biomarkers to differentiate early-stage colorectal cancer (CRC) from benign colorectal disease (BCD) and healthy controls. Materials & Methods: Quantitative and qualitative analysis of C(16:1), C(18:3), C(18:2), C(18:1), C(20:4), and C(22:6) in 185 healthy controls, 55 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaping, He, Chengyan, Qiu, Ling, Wang, Yanmin, Qin, Xuzhen, Liu, Yujie, Li, Zhili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749369/
https://www.ncbi.nlm.nih.gov/pubmed/26918062
http://dx.doi.org/10.7150/jca.13870
Descripción
Sumario:Background: To screen biomarkers to differentiate early-stage colorectal cancer (CRC) from benign colorectal disease (BCD) and healthy controls. Materials & Methods: Quantitative and qualitative analysis of C(16:1), C(18:3), C(18:2), C(18:1), C(20:4), and C(22:6) in 185 healthy controls, 55 patients with BCD, and 139 patients with CRC was performed. Comparisons of their levels in between CRC patients, BCD patients, and healthy controls were performed using Mann-Whitney U test. Results: Serum levels of C(16:1), C(18:3), C(18:2), C(18:1), C(20:4), and C(22:6) in CRC patients were significantly decreased compared with healthy controls and BCD patients. A combination of C(16:1), C(18:2), C(20:4), and C(22:6) has excellent diagnostic performance to differentiate early-stage CRC patients from healthy controls plus BCD patients, with an AUC of 0.926, a sensitivity of 84.6%, and a specificity of 89.8%. Conclusions: Serum levels of C(16:1), C(18:2), C(20:4), and C(22:6 )could be diagnostic indicators of early-stage CRC patients.

Ejemplares similares